BLA 125293 · Horizon Pharma
Krystexxa
Pegloticase · Injection · Uric Acid-specific Enzyme
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Aug 7, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2010
Sep 14, 2010
Approved uses
2
Original approval plus efficacy supplements
Registered trials
22
4 Phase 3, 1 recruiting
FAERS reports
3,875
1,895 serious, 135 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: ANAPHYLAXIS and INFUSION REACTIONS, G6PD DEFICIENCY ASSOCIATED HEMOLYSIS and METHEMOGLOBINEMIA Anaphylaxis and infusion reactions have been reported to occur during and after administration of KRYSTEXXA. ( 5.1 , 5.2 ) Anaphylaxis may occur with any infusion, and generally manifests within 2 hours of the infusion. However, delayed hypersensitivity reactions have also been reported. ( 5.1 ) KRYSTEXXA should be administered in healthcare settings and by healthcare providers prepared to manage anaphylaxis and infusion reactions. ( 5.1 , 5.2 ) Premedicate with antihistamines and corticosteroids and closely monitor for anaphylaxis for an appropriate period of time after administration of KRYSTEXXA. ( 5.1 , 5.2 ) Monitor serum uric acid levels prior to each infusion and discontinue treatment if levels increase to above 6 mg/dL, particularly when 2 consecutive levels above 6 mg/dL are...
What it is approved for
From the label in effect Nov 2, 2026.
KRYSTEXXA ® (pegloticase) is indicated, for the treatment of chronic gout in adult patients refractory to conventional therapy. Gout refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated. KRYSTEXXA ® (pegloticase) is a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy. ( 1 ) Limitations of Use: KRYSTEXXA is not recommended for the treatment of asymptomatic hyperuricemia. ( 1 ) Limitations of Use: KRYSTEXXA is not recommended for the treatment of asymptomatic hyperuricemia.
Mechanism: KRYSTEXXA is a uric acid specific enzyme which is a recombinant uricase and achieves its therapeutic effect by catalyzing the oxidation of uric acid to allantoin, thereby lowering serum uric acid. Allantoin is an inert and water-soluble purine metabolite; it is readily eliminated, primarily by renal excretion.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 7, 2022 Supplement 104 · Efficacy · priority review OrphanLetterLabelMedication Guide
- Sep 14, 2010 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelReviewSummary Review
1 products under this application
- KRYSTEXXA · PEGLOTICASE 8MG · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Pegloticase" as an intervention, any sponsor and status, largest first.
- A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory GoutPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT06229145 · 306 participants · Start Mar 18, 2024 · Primary completion Jul 30, 2025
Drug: Pegloticase; Methotrexate · For: Gout
Sites: Birmingham, Alabama; Anchorage, Alaska; Chandler, Arizona · 74 sites in all
AmgenAmgen (AMGN)
NCT07388498 · 270 participants (planned) · Start Feb 9, 2026 · Primary completion Jun 18, 2028
Drug: Pegloticase; Methotrexate · For: Uncontrolled Gout
Sites: Birmingham, Alabama; Anchorage, Alaska; Searcy, Arkansas · 75 sites in all
- Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic GoutPivotal-lookingCompleted
Savient PharmaceuticalsIndustry
NCT00325195 · 225 participants · Start May 2006 · Primary completion Oct 2007
Drug: pegloticase · For: Gout
Sites: Birmingham, Alabama; Tucson, Arizona; Jonesboro, Arkansas · 56 sites in all
AmgenAmgen (AMGN)
NCT04511702 · 191 participants · Start Oct 2, 2020 · Primary completion Jan 18, 2024
Drug: Pegloticase with MTX · For: Chronic Uncontrolled Gout; Gout; Uncontrolled Gout
Sites: Birmingham, Alabama; Anchorage, Alaska; Gilbert, Arizona · 39 sites in all
- A Study to Compare the Efficacy of SEL-212 to KRYSTEXXA® in Gout Participants Refractory to Conventional TherapyPivotal-lookingCompleted
Selecta Biosciences, Inc.Industry
NCT03905512 · 170 participants · Start May 7, 2019 · Primary completion Aug 5, 2020
Drug: SEL-212; KRYSTEXXA® · For: Chronic Gout
Sites: Anniston, Alabama; Sun City, Arizona; Little Rock, Arkansas · 43 sites in all
- Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled GoutPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT03994731 · 152 participants · Start Jun 13, 2019 · Primary completion Mar 17, 2021
Drug: Pegloticase; methotrexate and 5 more · For: Gout
Sites: Birmingham, Alabama; Anchorage, Alaska; Flagstaff, Arizona · 60 sites in all
- Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic GoutPivotal-lookingCompleted
Savient PharmaceuticalsIndustry
NCT01356498 · 151 participants · Start Dec 2006 · Primary completion Jan 2010
Drug: pegloticase · For: Gout
Sites: San Francisco, California; Santa Maria, California; Whittier, California · 22 sites in all
Ampel BioSolutions, LLCIndustry
NCT02598596 · 132 participants · Start Dec 2015 · Primary completion Apr 13, 2020
Drug: Pegloticase; Azathioprine · For: Gout
Sites: Birmingham, Alabama; Huntsville, Alabama; Wheaton, Maryland · 11 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- gout575
- blood uric acid increased417
- infusion related reaction367
- therapeutic response decreased240
- dyspnoea184
- drug ineffective155
- nausea150
- urticaria150
- off label use138
- pruritus138
- rash133
- dizziness117
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2011 | 52 |
| 2012 | 78 |
| 2013 | 98 |
| 2014 | 57 |
| 2015 | 48 |
| 2016 | 96 |
| 2017 | 104 |
| 2018 | 264 |
| 2019 | 384 |
| 2020 | 240 |
| 2021 | 101 |
| 2022 | 351 |
| 2023 | 426 |
| 2024 | 582 |
| 2025 | 473 |
| 2026 | 521 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Krystexxa (PEGloticase)
2024 spending
$212M
Beneficiaries
662
4,801 claims
Per beneficiary
$320,769
$28,898.90 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $49,727,178 |
| 2021 | $68,263,090 |
| 2022 | $123,038,866 |
| 2023 | $178,838,011 |
| 2024 | $212,349,150 |
Part B: Krystexxa (Pegloticase) · HCPCS J2507
2024 spending
$283M
Beneficiaries
1,097
10,614 claims
Per beneficiary
$257,821
2024 ASP limit $3,423.05 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $142,198,168 |
| 2021 | $160,197,749 |
| 2022 | $201,220,453 |
| 2023 | $246,712,915 |
| 2024 | $282,830,140 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- 2016 updated EULAR evidence-based recommendations for the management of gout.
Richette P, Doherty M, Pascual E, et al. · Ann Rheum Dis 2017 · Practice Guideline, Systematic Review
- Pegloticase for chronic gout.
Anderson A, Singh JA · Cochrane Database Syst Rev 2010 · Systematic Review
- A Randomized, Placebo-Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings.
Botson JK, Saag K, Peterson J, et al. · Arthritis Rheumatol 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Interventions for tophi in gout.
Sriranganathan MK, Vinik O, Bombardier C, et al. · Cochrane Database Syst Rev 2014 · Research Support, Non-U.S. Gov't, Systematic Review
- Interventions for tophi in gout.
Sriranganathan MK, Vinik O, Pardo Pardo J, et al. · Cochrane Database Syst Rev 2021 · Research Support, Non-U.S. Gov't, Systematic Review
- Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.
Sundy JS, Baraf HS, Yood RA, et al. · JAMA 2011 · Multicenter Study, Randomized Controlled Trial
Sponsor: Amgen
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.